isomethyleugenol has been researched along with Chronic Progressive Multiple Sclerosis in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianco, A; De Fino, C; Losavio, F; Lucchini, M; Mirabella, M; Nociti, V; Sabino, A; Santoro, M | 1 |
1 trial(s) available for isomethyleugenol and Chronic Progressive Multiple Sclerosis
| Article | Year |
|---|---|
Sativex® effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
Topics: Cannabidiol; Dronabinol; Drug Combinations; Female; Humans; Interferon beta-1b; Leukocytes, Mononuclear; Male; Methylation; Middle Aged; Multiple Sclerosis, Chronic Progressive; Promoter Regions, Genetic; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2017 |